1. Home
  2. DGICA vs TBPH Comparison

DGICA vs TBPH Comparison

Compare DGICA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DGICA
  • TBPH
  • Stock Information
  • Founded
  • DGICA 1986
  • TBPH 2013
  • Country
  • DGICA United States
  • TBPH United States
  • Employees
  • DGICA N/A
  • TBPH N/A
  • Industry
  • DGICA Property-Casualty Insurers
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • DGICA Finance
  • TBPH Health Care
  • Exchange
  • DGICA Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • DGICA 516.7M
  • TBPH 485.8M
  • IPO Year
  • DGICA N/A
  • TBPH N/A
  • Fundamental
  • Price
  • DGICA $15.56
  • TBPH $9.59
  • Analyst Decision
  • DGICA
  • TBPH Buy
  • Analyst Count
  • DGICA 0
  • TBPH 4
  • Target Price
  • DGICA N/A
  • TBPH $13.75
  • AVG Volume (30 Days)
  • DGICA 139.9K
  • TBPH 217.1K
  • Earning Date
  • DGICA 02-20-2025
  • TBPH 11-12-2024
  • Dividend Yield
  • DGICA 4.43%
  • TBPH N/A
  • EPS Growth
  • DGICA 148.60
  • TBPH N/A
  • EPS
  • DGICA 0.74
  • TBPH N/A
  • Revenue
  • DGICA $979,119,004.00
  • TBPH $63,192,000.00
  • Revenue This Year
  • DGICA N/A
  • TBPH $11.41
  • Revenue Next Year
  • DGICA $5.78
  • TBPH $37.36
  • P/E Ratio
  • DGICA $20.89
  • TBPH N/A
  • Revenue Growth
  • DGICA 7.44
  • TBPH 15.93
  • 52 Week Low
  • DGICA $12.26
  • TBPH $7.44
  • 52 Week High
  • DGICA $17.00
  • TBPH $11.71
  • Technical
  • Relative Strength Index (RSI)
  • DGICA 36.76
  • TBPH 50.13
  • Support Level
  • DGICA $16.13
  • TBPH $9.62
  • Resistance Level
  • DGICA $16.76
  • TBPH $10.08
  • Average True Range (ATR)
  • DGICA 0.41
  • TBPH 0.31
  • MACD
  • DGICA -0.15
  • TBPH -0.06
  • Stochastic Oscillator
  • DGICA 3.36
  • TBPH 25.00

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: